IMMUNE CHECKPOINT INHIBITOR
Clinical trials for IMMUNE CHECKPOINT INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new IMMUNE CHECKPOINT INHIBITOR trials appear
Sign up with your email to follow new studies for IMMUNE CHECKPOINT INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation to the gut boosts cancer-killing power of immunotherapy in esophageal cancer trial
Disease control Recruiting nowThis study tests whether adding a single, low dose of radiation to the small intestine can make a standard immunotherapy-plus-chemotherapy regimen work better for people with esophageal cancer that cannot be easily removed by surgery. About 43 adults with borderline resectable or…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE2 • Sponsor: Chuangzhen Chen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to boost immunotherapy in elderly melanoma patients
Disease control Recruiting nowThis Phase 2 trial tests whether adding thymosin alpha 1 to the immunotherapy drug toripalimab can help elderly patients (60+) with advanced melanoma. The study will enroll 55 participants and measure how many patients' tumors shrink or disappear. Researchers also want to see if …
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo could shrink tumors and reduce radiation side effects in nose cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding an immunotherapy drug (cadonilimab) and low-dose radiation to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 380 participants will be randomly assigned to receive either the new combination …
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New radiation 'Lattice' method paired with immunotherapy shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Immunotherapy plus radiation aims to stop liver cancer recurrence
Disease control Recruiting nowThis phase 3 trial tests whether combining radiotherapy with the immunotherapy drug sintilimab can better prevent liver cancer from coming back after surgery, compared to the standard TACE procedure. The study enrolls 286 adults with high-risk features like narrow surgical margin…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New rad combo targets kidney cancer after immunotherapy fails
Disease control Recruiting nowThis phase 2 trial is testing a combination of high-dose and low-dose radiotherapy, plus an immunotherapy drug, in 35 people with kidney cancer that got worse after prior immunotherapy. The goal is to see if this approach can control the disease and how safe it is. Participants w…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 26, 2026 13:10 UTC
-
Blood test may predict immunotherapy success in advanced cancers
Knowledge-focused Recruiting nowThis study is observing 50 adults with advanced cancers (lung, breast, colorectal, gastric, or liver) who are starting immunotherapy. Researchers want to see if changes in ctDNA (bits of tumor DNA in the blood) can predict early whether the treatment is working. They will also ch…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Sponsor: Gene Solutions • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC